Algorithm of Golgi Protein 73 and Liver Stiffness Accurately Diagnoses Significant Fibrosis in Chronic HBV Infection
Zhujun Cao,Ziqiang Li,Hui Wang,Yuhan Liu,Yumin Xu,Ruidong Mo,Peipei Ren,Lichang Chen,Jie Lu,Hong Li,Yan Zhuang,Yunye Liu,Xiaolin Wang,Gangde Zhao,Weiliang Tang,Xiaogang Xiang,Wei Cai,Longgen Liu,Shisan Bao,Qing Xie
DOI: https://doi.org/10.1111/liv.13536
IF: 8.754
2017-01-01
Liver International
Abstract:Background & AimsSerum Golgi protein 73 (GP73) is a potential biomarker for fibrosis assessment. We aimed to develop an algorithm based on GP73 and liver stiffness (LS) for further improvement of accuracy for significant fibrosis in patients with antiviral-naive chronic hepatitis B virus (HBV) infection. MethodsDiagnostic accuracy evaluation of GP73 and development of GP73-LS algorithm was performed in training cohort (n=267) with an independent cohort (n=133) for validation. ResultsA stepwise increasing pattern of serum GP73 was observed across fibrosis stages in patients with antiviral-naive chronic HBV infection. Serum GP73 significantly correlated (rho=0.48, P<.001) with fibrosis stage and was an independent predictor for the presence of significant fibrosis (OR, 95%CI: 1.02, 1.01-1.03, per increase in 1ng/mL, P<.001). Both LS (AUROC, 95%CI: 0.82, 0.77-0.87, accuracy: 74.7%) and GP73 (AUROC, 95%CI: 0.76, 0.71-0.82, accuracy: 71.5%) well-predicted significant fibrosis and outperformed APRI (AUROC, 95%CI: 0.69, 0.63-0.76, accuracy: 66%) and FIB-4 (AUROC, 95%CI: 0.66, 0.60-0.73, accuracy: 63.6%). Using GP73-LS algorithm, GP73<63 in agreement with LS<8.5 provided accuracy of 81.7% to excluded significant fibrosis. GP7363 in agreement with LS8.5 provided accuracy of 93.3% to confirm significant fibrosis. Almost 64% or 68% of patients in the training or validation cohort could be accurately classified. ConclusionsSerum GP73 is a robust biomarker for significant fibrosis diagnosis. GP73-LS algorithm provided better diagnostic accuracy than currently available approaches. More than 60% antiviral naive CHB patients could use this algorithm without resorting to liver biopsy. See Editorial on Page 1605